Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Flippot

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Bulletin Du Cancer|August 16, 2017
[The breakthrough of personalized medicine, new hopes and new challenges]Ronan Flippot, Christophe Massard, Edouard Auclin, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerPernelle Lavaud, Clément Dumont, Constance Thibault, et al.
Bulletin Du Cancer|June 27, 2022
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinomaRonan Flippot, Violaine Gorgeu, Marc Pujalte, et al.
International Journal of Cancer|February 7, 2026
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and PortugalJose C Tapia, Javier Gavira, Diana Matthews, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2021
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell CarcinomaRitesh R Kotecha, Ronan Flippot, Taylor Nortman, et al.
Investigational New Drugs|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinomaBradley A McGregor, Michael Gordon, Ronan Flippot, et al.
Clinical Genitourinary Cancer|February 3, 2026
Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World AnalysisPatricia Rioja, Macarena Rey-Cárdenas, Jorge Esteban-Villarrubia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2025
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacyRoman Vion, Matthieu Roulleaux-Dugage, Ronan Flippot, et al.
Prostate Cancer and Prostatic Diseases|June 19, 2024
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancerJennifer Le Guevelou, Francesco Cuccia, Ronan Flippot, et al.
Exploration of Targeted Anti-Tumor Therapy|October 28, 2024
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinomaLoubna Omri, Marie Naigeon, Ronan Flippot, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Bulletin Du Cancer|August 16, 2017
[The breakthrough of personalized medicine, new hopes and new challenges]Ronan Flippot, Christophe Massard, Edouard Auclin, et al.
Therapeutic Advances in Medical Oncology|January 25, 2021
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancerPernelle Lavaud, Clément Dumont, Constance Thibault, et al.
Bulletin Du Cancer|June 27, 2022
Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinomaRonan Flippot, Violaine Gorgeu, Marc Pujalte, et al.
International Journal of Cancer|February 7, 2026
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and PortugalJose C Tapia, Javier Gavira, Diana Matthews, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2021
Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell CarcinomaRitesh R Kotecha, Ronan Flippot, Taylor Nortman, et al.
Investigational New Drugs|May 31, 2020
Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinomaBradley A McGregor, Michael Gordon, Ronan Flippot, et al.
Clinical Genitourinary Cancer|February 3, 2026
Clinical Outcomes of Targeted Therapies Following HIF-2α Inhibition in Metastatic Renal Cell Carcinoma: A Real-World AnalysisPatricia Rioja, Macarena Rey-Cárdenas, Jorge Esteban-Villarrubia, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2025
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacyRoman Vion, Matthieu Roulleaux-Dugage, Ronan Flippot, et al.
Prostate Cancer and Prostatic Diseases|June 19, 2024
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancerJennifer Le Guevelou, Francesco Cuccia, Ronan Flippot, et al.
Exploration of Targeted Anti-Tumor Therapy|October 28, 2024
Blood-based circulating biomarkers for prediction of immune-checkpoint inhibitors efficacy in renal cell carcinomaLoubna Omri, Marie Naigeon, Ronan Flippot, et al.
Pageof 8